Aptabio Obtains Patent for New Substance Potentially Developable as Inflammation Treatment Agent
[Asia Economy Reporter Kum Boryeong] Aptabio announced on the 19th that it has obtained an Australian patent related to the 'new crystalline solid compound of 3-Phenyl-4-propyl-1-(pyridin-2-yl)-1H-pyrazol-5-ol hydrochloride.'
Hot Picks Today
"Buy on Black Monday"... Japan's Nomura Forecasts 590,000 for Samsung, 4 Million for SK hynix
- "Plunged During the War, Now Surging Again"... The Real Reason Behind the 6% One-Day Silver Market Rally [Weekend Money]
- "Trump and Netanyahu Hold Talks on Iran War...Possibility of Resuming Military Action"
- Experts Are Already Watching Closely..."Target Stock Price 970,000 Won" Now Only the Uptrend Remains [Weekend Money]
- "That? It's Already Stashed" Nightlife Scene Crosses the Line [ChwiYak Nation] ③
Aptabio stated, "This patent can be developed as a treatment for inflammatory and fibrotic diseases such as diabetic nephropathy and non-alcoholic steatohepatitis (NASH)," adding, "We plan to develop various treatments for inflammatory and fibrotic diseases using this compound."
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
